J. Curtin

发表

p53 in human embryonal carcinoma: identification of a transferable, transcriptional repression domain in the N-terminal region of p53

J. Curtin, M. Spinella, 2005, Oncogene.

Positive and negative regulation of deltaN-p63 promoter activity by p53 and deltaN-p63-alpha contributes to differential regulation of p53 target genes.

J. Lamb, Emma A. Lubin, J. Curtin, 2003, Oncogene.

Retinoic acid activates p53 in human embryonal carcinoma through retinoid receptor-dependent stimulation of p53 transactivation function

E. Dmitrovsky, J. Curtin, M. Spinella, 2001, Oncogene.

Critical role of kinase activity of hematopoietic progenitor kinase 1 in anti-tumor immune surveillance

J. Hunt, B. Warrack, M. Reily, 2019, PloS one.

Amivantamab in EGFR Exon 20 Insertion–Mutated Non–Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study

N. Girard, R. Govindan, Keunchil Park, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Enhanced antitumor immunity by a novel small molecule HPK1 inhibitor

E. Lees, R. Bhadra, J. Hunt, 2021, Journal for ImmunoTherapy of Cancer.

Interaction with host SGS 3 is required for suppression of RNA silencing by tomato yellow leaf curl virus V 2 protein

M. Lazar, D. Steger, D. Gidoni, 2009 .

Clinical validation of companion diagnostics for the selection of patients with non-small cell lung cancer tumors harboring epidermal growth factor receptor exon 20 insertion mutations for treatment with amivantamab.

T. Jatkoe, J. Curtin, J. Odegaard, 2022, The Journal of molecular diagnostics : JMD.

Rev-erbα, a Heme Sensor That Coordinates Metabolic and Circadian Pathways

R. A. Reid, M. Lazar, K. Pearce, 2007, Science.

Retinoid target gene activation during induced tumor cell differentiation: human embryonal carcinoma as a model.

J. Curtin, M. Spinella, J. S. Kerley, 2003, The Journal of nutrition.

Amivantamab and lazertinib in patients with EGFR-mutant non–small cell lung (NSCLC) after progression on osimertinib and platinum-based chemotherapy: Updated results from CHRYSALIS-2.

L. Trani, Y. Ohe, E. Felip, 2022, Journal of Clinical Oncology.

Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR-cMet Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion-Driven NSCLC.

S. Heo, S. Lim, B. Cho, 2020, Cancer discovery.

Re-expression of GATA2 Cooperates with Peroxisome Proliferator-activated Receptor-γ Depletion to Revert the Adipocyte Phenotype*

J. Schug, N. McKenna, M. Lazar, 2009, Journal of Biological Chemistry.

P76.73 MARIPOSA: Randomized Phase 3 Study of First-line Amivantamab + Lazertinib vs Osimertinib vs Lazertinib in EGFR-mutant NSCLC

S. Shreeve, K. Patel, J. Curtin, 2021 .

Amivantamab in combination with lazertinib for the treatment of osimertinib-relapsed, chemotherapy-naïve EGFR mutant (EGFRm) non-small cell lung cancer (NSCLC) and potential biomarkers for response.

S. Ou, Keunchil Park, E. Cho, 2021 .

Novel drug discovery opportunities for colorectal cancer

J. Curtin, 2013, Expert opinion on drug discovery.

Retinol saturase promotes adipogenesis and is downregulated in obesity

Stefan Engeli, M. Lazar, D. Steger, 2009, Proceedings of the National Academy of Sciences.

A Widely Used Retinoic Acid Receptor Antagonist Induces Peroxisome Proliferator-Activated Receptor-γ Activity

M. Lazar, J. Curtin, M. Schupp, 2007, Molecular Pharmacology.

Rev-erbalpha, a heme sensor that coordinates metabolic and circadian pathways.

R. A. Reid, M. Lazar, K. Pearce, 2007, Science.

Drug Discovery Approaches to Target Wnt Signaling in Cancer Stem Cells

J. Curtin, M. V. Lorenzi, 2010, Oncotarget.

Positive and negative regulation of ΔN-p63 promoter activity by p53 and ΔN-p63-α contributes to differential regulation of p53 target genes

J. Lamb, Emma A. Lubin, J. Curtin, 2003, Oncogene.

Frequency, underdiagnosis, and heterogeneity of epidermal growth factor receptor exon 20 insertion mutations using real‐world genomic datasets

S. Ou, L. Bazhenova, J. Curtin, 2022, Molecular oncology.

Amivantamab in patients with NSCLC with MET exon 14 skipping mutation: Updated results from the CHRYSALIS study.

A. Mansfield, S. Ou, R. Salgia, 2022, Journal of Clinical Oncology.

JNJ-61186372 (JNJ-372), an EGFR-cMet bispecific antibody, in EGFR-driven advanced non-small cell lung cancer (NSCLC).

R. Govindan, Keunchil Park, E. Cho, 2019, Journal of Clinical Oncology.

P76.74 PAPILLON: Randomized Phase 3 Study of Amivantamab Plus Chemotherapy vs Chemotherapy Alone in EGFR Exon20ins NSCLC

K. Patel, J. Curtin, A. Roshak, 2021 .

P24.14 Validation of Companion Diagnostics for the Identification of Patients with EGFR Exon20ins NSCLC for Amivantamab Therapy

T. Jatkoe, J. Curtin, J. Odegaard, 2021, Journal of Thoracic Oncology.

Predictive biomarkers for treatment with amivantamab plus lazertinib among EGFR-mutated NSCLC in the post-osimertinib setting: Analysis of tissue IHC and ctDNA NGS.

T. Jatkoe, S. Ou, E. Felip, 2023, Journal of Clinical Oncology.

Amivantamab plus lazertinib in osimertinib-relapsed EGFR-mutant advanced non-small cell lung cancer: a phase 1 trial

S. Ou, Keunchil Park, Dong-Wan Kim, 2023, Nature Medicine.